Possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)

A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab's blockage of VEGF-A to continue to drive tumor growth. "Think of it like damming a river...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Colorectal Cancer Source Type: news